INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zynex, Inc. - ZYXI
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zynex, Inc. - ZYXI |
[17-March-2025] |
NEW YORK, March 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zynex, Inc. ("Zynex" or the "Company") (NASDAQ: ZYXI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Zynex and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On March 11, 2025, Zynex reported its fourth quarter and full year 2024 financial results, revealing a revenue "shortfall" in the quarter "due to slower than normal payments from certain payers." Zynex also revealed that Tricare, the healthcare program for uniformed service members that "currently represents approximately 20-25% of [the Company's] annual revenue", "has temporarily suspended payments as they review prior claims." On this news, Zynex's stock price fell $3.59 per share, or 51.3%, to close at $3.41 per share on March 12, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:
SOURCE Pomerantz LLP | ||
Company Codes: NASDAQ-NMS:ZYXI |